Stock Research: Alkem Laboratories

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Alkem Laboratories

BSE:539523 INE540L01014
58
  • Value
    55
  • Growth
    55
  • Safety
    Safety
    39
  • Combined
    43
  • Sentiment
    74
  • 360° View
    360° View
    58
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Alkem Laboratories Ltd. is an India-based pharmaceutical company focused on developing, manufacturing, and selling pharmaceutical products. The company operates in pharmaceuticals, producing branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, with offerings in various medical fields including anti-infectives, cardiology, oncology, and more. It markets products in India and over 40 international markets, with the United States as a key focus. In the last fiscal year, the company had a market cap of $6958 millions, profits of $960 millions, and revenue of $1517 millions.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 58 (better than 58% compared with alternatives), overall professional sentiment and financial characteristics for the stock Alkem Laboratories are above average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Alkem Laboratories. The consolidated Growth Rank has a good rank of 55, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 55% of competitors in the same industry. The consolidated Safety Rank at 55 means that the company has a financing structure that is safer than 55% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 74, which means that professional investors are more optimistic about the stock than for 74% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 39, meaning that the share price of Alkem Laboratories is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 61% of alternative stocks in the same industry. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Nov-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
39 61 51 71
Growth
55 25 97 37
Safety
Safety
55 46 42 57
Sentiment
74 27 80 26
360° View
360° View
58 22 88 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
31 15 25 62
Opinions Change
52 31 50 13
Pro Holdings
n/a 42 83 20
Market Pulse
81 54 83 67
Sentiment
74 27 80 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
39 61 51 71
Growth
55 25 97 37
Safety Safety
55 46 42 57
Combined
43 28 85 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
38 58 38 64
Price vs. Earnings (P/E)
45 48 50 59
Price vs. Book (P/B)
39 45 44 54
Dividend Yield
58 56 47 62
Value
39 61 51 71
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
56 48 44 39
Profit Growth
54 47 86 34
Capital Growth
13 16 79 73
Stock Returns
75 35 91 47
Growth
55 25 97 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
54 44 48 44
Refinancing
61 60 62 64
Liquidity
52 47 37 57
Safety Safety
55 46 42 57

Similar Stocks

Discover high‑ranked alternatives to Alkem Laboratories and broaden your portfolio horizons.

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

UPL

BSE:512070
Country: India
Industry: Fertilizers & Agricultural Chemicals
Size: Large
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.